XYDC2050 (Compound 29) is a selective vasopressin V2 receptor (V2R) antagonist, with an IC50 of 27 nM and a Ki of 2.8 nM. It exhibits a Ki of 420.7 nM for V1R with a selectivity index of 162. XYDC2050 inhibits vasopressin-induced intracellular cyclic adenosine monophosphate (cAMP) accumulation with an IC50 of 12 nM. This compound can suppress kidney cyst growth, reduce kidney-to-body weight ratio, and decrease cyst area and cystic index, making it a candidate for autosomal dominant polycystic kidney disease (ADPKD) research.
Target:
Vasopressin Receptor
* VAT and and shipping costs not included. Errors and price changes excepted
